Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ACAD's Cash-to-Debt is ranked higher than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ACAD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ACAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.56  Med: 970.25 Max: 98090
Current: No Debt
5.56
98090
Equity-to-Asset 0.91
ACAD's Equity-to-Asset is ranked higher than
88% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ACAD: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
ACAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.13  Med: 0.79 Max: 0.98
Current: 0.91
-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACAD' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 41.09
Beneish M-Score: 473.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -954.71
ACAD's Operating Margin % is ranked lower than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ACAD: -954.71 )
Ranked among companies with meaningful Operating Margin % only.
ACAD' s Operating Margin % Range Over the Past 10 Years
Min: -269855.74  Med: -1339.85 Max: 35.82
Current: -954.71
-269855.74
35.82
Net Margin % -948.93
ACAD's Net Margin % is ranked lower than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ACAD: -948.93 )
Ranked among companies with meaningful Net Margin % only.
ACAD' s Net Margin % Range Over the Past 10 Years
Min: -269578.69  Med: -1333.65 Max: 35.93
Current: -948.93
-269578.69
35.93
ROE % -64.26
ACAD's ROE % is ranked lower than
67% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ACAD: -64.26 )
Ranked among companies with meaningful ROE % only.
ACAD' s ROE % Range Over the Past 10 Years
Min: -138.68  Med: -63.43 Max: 72.43
Current: -64.26
-138.68
72.43
ROA % -59.83
ACAD's ROA % is ranked lower than
72% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ACAD: -59.83 )
Ranked among companies with meaningful ROA % only.
ACAD' s ROA % Range Over the Past 10 Years
Min: -78.95  Med: -55.21 Max: 34.38
Current: -59.83
-78.95
34.38
ROC (Joel Greenblatt) % -10221.23
ACAD's ROC (Joel Greenblatt) % is ranked lower than
87% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ACAD: -10221.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21643.52  Med: -9123.53 Max: 2028.76
Current: -10221.23
-21643.52
2028.76
3-Year Revenue Growth Rate 126.00
ACAD's 3-Year Revenue Growth Rate is ranked higher than
95% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ACAD: 126.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -77.6  Med: -34.55 Max: 126
Current: 126
-77.6
126
3-Year EBITDA Growth Rate 73.70
ACAD's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ACAD: 73.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53  Med: -11 Max: 73.7
Current: 73.7
-53
73.7
3-Year EPS without NRI Growth Rate 74.60
ACAD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ACAD: 74.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.6  Med: -5.35 Max: 74.6
Current: 74.6
-36.6
74.6
GuruFocus has detected 6 Warning Signs with ACADIA Pharmaceuticals Inc $ACAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACAD's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ACAD Guru Trades in Q2 2016

Steven Cohen 1,199,700 sh (-46.03%)
» More
Q3 2016

ACAD Guru Trades in Q3 2016

George Soros 17,645 sh (New)
Jana Partners 149,252 sh (New)
Steven Cohen 2,071,500 sh (+72.67%)
Steven Cohen 120,300 sh (unchged)
» More
Q4 2016

ACAD Guru Trades in Q4 2016

Joel Greenblatt 25,682 sh (New)
Jana Partners 301,243 sh (+101.84%)
George Soros Sold Out
Steven Cohen 1,225,000 sh (-40.86%)
» More
Q1 2017

ACAD Guru Trades in Q1 2017

Paul Singer 777,382 sh (New)
George Soros 8,900 sh (New)
Steven Cohen 1,931,200 sh (+57.65%)
Jana Partners 421,140 sh (+39.80%)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BLUE, OTCPK:BTGGF, NAS:CBPO, NAS:NKTR, NYSE:XON, NAS:ICPT, NAS:KITE, NAS:TECH, OTCPK:ABCZY, NAS:JUNO, NAS:GLPG, NAS:SAGE, NAS:RARE, NAS:LGND, NAS:AGIO, NAS:CLVS, NYSE:AXON, NAS:PTLA, NAS:PRTA, NAS:NBIX » details
Traded in other countries:DR6.Germany,
Headquarter Location:USA
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of medicines to address unmet medical needs in central nervous system disorders.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Ratios

vs
industry
vs
history
PB Ratio 7.27
ACAD's PB Ratio is ranked lower than
80% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ACAD: 7.27 )
Ranked among companies with meaningful PB Ratio only.
ACAD' s PB Ratio Range Over the Past 10 Years
Min: 0.48  Med: 5.41 Max: 16.67
Current: 7.27
0.48
16.67
PS Ratio 100.98
ACAD's PS Ratio is ranked lower than
92% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ACAD: 100.98 )
Ranked among companies with meaningful PS Ratio only.
ACAD' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 50.57 Max: 39600
Current: 100.98
0.66
39600
EV-to-EBIT -9.22
ACAD's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ACAD: -9.22 )
Ranked among companies with meaningful EV-to-EBIT only.
ACAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -73.5  Med: -4.9 Max: 6.3
Current: -9.22
-73.5
6.3
EV-to-EBITDA -9.29
ACAD's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ACAD: -9.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -73.7  Med: -5 Max: 6.1
Current: -9.29
-73.7
6.1
Current Ratio 10.82
ACAD's Current Ratio is ranked higher than
86% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ACAD: 10.82 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s Current Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.4 Max: 46.41
Current: 10.82
2.27
46.41
Quick Ratio 10.73
ACAD's Quick Ratio is ranked higher than
86% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ACAD: 10.73 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s Quick Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.4 Max: 46.41
Current: 10.73
2.27
46.41
Days Inventory 208.20
ACAD's Days Inventory is ranked lower than
82% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ACAD: 208.20 )
Ranked among companies with meaningful Days Inventory only.
ACAD' s Days Inventory Range Over the Past 10 Years
Min: 208.2  Med: 247.78 Max: 247.78
Current: 208.2
208.2
247.78
Days Sales Outstanding 85.73
ACAD's Days Sales Outstanding is ranked lower than
79% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ACAD: 85.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 85.73  Med: 1585.63 Max: 9801.15
Current: 85.73
85.73
9801.15
Days Payable 148.11
ACAD's Days Payable is ranked higher than
93% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ACAD: 148.11 )
Ranked among companies with meaningful Days Payable only.
ACAD' s Days Payable Range Over the Past 10 Years
Min: 148.11  Med: 464.35 Max: 464.35
Current: 148.11
148.11
464.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.00
ACAD's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ACAD: -10.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153  Med: -23.9 Max: -2
Current: -10
-153
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.84
ACAD's Price-to-Net-Cash is ranked lower than
61% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ACAD: 7.84 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACAD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 5.28 Max: 19.49
Current: 7.84
0
19.49
Price-to-Net-Current-Asset-Value 7.50
ACAD's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ACAD: 7.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACAD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 5.2 Max: 18.47
Current: 7.5
0
18.47
Price-to-Tangible-Book 7.37
ACAD's Price-to-Tangible-Book is ranked lower than
72% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ACAD: 7.37 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.63  Med: 4.86 Max: 18.19
Current: 7.37
0.63
18.19
Price-to-Median-PS-Value 2.00
ACAD's Price-to-Median-PS-Value is ranked lower than
94% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ACAD: 2.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.58 Max: 649.2
Current: 2
0
649.2
Earnings Yield (Greenblatt) % -10.84
ACAD's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ACAD: -10.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11  Med: 71.7 Max: 51153
Current: -10.84
-11
51153

More Statistics

Revenue (TTM) (Mil) $32.61
EPS (TTM) $ -2.61
Beta4.56
Short Percentage of Float24.82%
52-Week Range $20.68 - 42.49
Shares Outstanding (Mil)122.05

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 82 234 487
EPS ($) -2.76 -1.54 0.13
EPS without NRI ($) -2.76 -1.54 0.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Insiders Roundup: Facebook, Twitter, Kellogg Feb 17 2017 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Acadia Has Tough Road Ahead With Nuplazid Success Mar 14 2015 
Analysts Remain Bullish on Acadia Pharma Despite Drug Approval Delay Mar 13 2015 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Edited Transcript of ACAD earnings conference call or presentation 9-May-17 9:00pm GMT May 11 2017
The Acadia Sell-off Is Overdone May 10 2017
Is This Why Acadia Pharmaceuticals Inc. Is Plunging Today? May 10 2017
Acadia reports 1Q loss May 09 2017
ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results May 09 2017
Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call May 09 2017
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on... May 08 2017
What to do when your biotechnology stock gets hit by takeover rumors May 04 2017
What's in the Cards for ACADIA (ACAD) this Earnings Season? May 02 2017
ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 May 02 2017
ETFs with exposure to ACADIA Pharmaceuticals, Inc. : May 1, 2017 May 01 2017
Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment... Apr 25 2017
Biotech M&A Plunges as Trump Attacks Drug Companies Apr 24 2017
ETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 19, 2017 Apr 19 2017
What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track Mar 31 2017
ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief... Mar 30 2017
ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on... Mar 29 2017
3 Top Biotech Stocks to Buy in 2017 Mar 26 2017
Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology Mar 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}